Recent Updates — FBIO

On September 30, 2026, Fortress Biotech repaid the remaining $15.0 million in outstanding principal under its senior secured credit agreement with Oaktree Fund Administration, LLC, along with approximately $435,000 in accrued interest and a $150,000 prepayment fee. This full repayment satisfied all indebtedness under the facility, resulting in the release of all liens and security interests on company property and the automatic termination of the agreement. The credit facility was originally entered into on July 25, 2024, with amendments occurring on December 12, 2025, and February 22, 2026. Fortress Biotech operates in the biotechnology industry, focusing on the acquisition and development of late-stage pharmaceutical assets.